Medline (NASDAQ:MDLN) Upgraded by BTIG Research to Strong-Buy Rating

BTIG Research upgraded shares of Medline (NASDAQ:MDLN) to a strong-buy rating in a report released on Monday morning, Marketbeat reports.

A number of other equities analysts have also weighed in on the company. William Blair assumed coverage on Medline in a research note on Monday. They issued an “outperform” rating for the company. Stifel Nicolaus assumed coverage on Medline in a report on Monday. They issued a “buy” rating and a $46.00 price target on the stock. Robert W. Baird initiated coverage on shares of Medline in a report on Monday. They set an “outperform” rating and a $48.00 price objective for the company. TD Cowen began coverage on shares of Medline in a research report on Monday. They set a “buy” rating and a $46.00 price objective on the stock. Finally, Royal Bank Of Canada initiated coverage on shares of Medline in a research report on Monday. They set an “outperform” rating and a $47.00 target price for the company. Eight equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $46.70.

Medline Stock Performance

Shares of Medline stock opened at $42.72 on Monday. Medline has a fifty-two week low of $34.89 and a fifty-two week high of $45.50.

Insider Activity at Medline

In other Medline news, Director Andrew J. Mills bought 2,586,206 shares of Medline stock in a transaction dated Thursday, December 18th. The shares were purchased at an average cost of $29.00 per share, for a total transaction of $74,999,974.00. Following the acquisition, the director directly owned 2,586,206 shares in the company, valued at approximately $74,999,974. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Charles N. Mills purchased 2,579,310 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was acquired at an average cost of $29.00 per share, with a total value of $74,799,990.00. Following the acquisition, the director owned 2,441,379 shares in the company, valued at $70,799,991. The trade was a -1,870.00% increase in their position. The disclosure for this purchase is available in the SEC filing.

Medline News Roundup

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Numerous analysts initiated buy/overweight ratings (Barclays, Jefferies, Bank of America, JPMorgan, Wolfe, Mizuho, TD Cowen, Stifel, Piper Sandler, Bernstein, J.P. Morgan, William Blair, Robert W. Baird, Truist). Several targets sit in the $46–$52 range, implying notable upside and helping fuel buying interest. Medline Stock Surges on Post‑IPO Buy Notes
• Positive Sentiment: Jefferies highlighted Medline’s $25 billion supply‑chain scale and gave a “buy” in its coverage debut — a validation of the company’s scale and margin expansion thesis that investors favor. Jefferies Coverage
• Positive Sentiment: Benzinga and other outlets note Medline raised ~$7 billion in its IPO and is being praised for a “prime vendor” model, branded mix shift and margin expansion potential — fundamental reasons analysts cite for buy ratings. Analysts Say Medline Has The Secret Sauce
• Neutral Sentiment: Valuation checks and commentary: several writeups assess MDLN near discounted cash‑flow estimates or “fairly priced” after the recent stability — these limit runaway upside and suggest gains are tied to multiple expansion as much as earnings. Valuation Check
• Neutral Sentiment: Short interest report in the period shows effectively zero/ambiguous data (odd reporting numbers). No clear short‑squeeze signal — treat short‑interest data as non‑contributory for now.
• Negative Sentiment: Some shops initiated neutral/hold ratings with lower targets (BNP Paribas $38 target, Deutsche Bank $40, Wells Fargo $42, Rothschild $42). Those lower targets cap consensus upside and could pressure the stock if follow‑through selling emerges.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.